These vaccines utilize tumor‐specific antigens (referred to as protein fragments or peptides), such as PSA, PAP, and PSMA in PCa, to trigger the immune system, promoting the production of targeted antibodies or cytotoxic T lymphocytes (also known as killer T cells) for the destruction of tumor cells bearing these specific antigens. This evidence concerns the gene FOLH1 and posterior cortical atrophy.